IL3RA and acute myeloid leukemia: CD123-CART cells show antitumor activity in CD123+ AML cell lines and primary patient AML cells in vitro and in vivo, and CD123-CART cells have limited toxicity in normal BM HSPCs, indicating a safety profile.